GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Beneish M-Score

Invitae (Invitae) Beneish M-Score : -6.58 (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Invitae Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -6.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Invitae's Beneish M-Score or its related term are showing as below:

NVTAQ' s Beneish M-Score Range Over the Past 10 Years
Min: -60.18   Med: -2.33   Max: 4.39
Current: -6.58

During the past 11 years, the highest Beneish M-Score of Invitae was 4.39. The lowest was -60.18. And the median was -2.33.


Invitae Beneish M-Score Historical Data

The historical data trend for Invitae's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Beneish M-Score Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.20 -2.74 -1.43 -2.59 -3.11

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.90 -3.11 -3.79 -3.50 -6.58

Competitive Comparison of Invitae's Beneish M-Score

For the Diagnostics & Research subindustry, Invitae's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Invitae's Beneish M-Score falls into.



Invitae Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Invitae for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9995+0.528 * 0.7051+0.404 * 0.1046+0.892 * 0.9262+0.115 * 0.7006
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9498+4.679 * -0.58309-0.327 * 3.3203
=-6.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $82.5 Mil.
Revenue was 121.241 + 120.532 + 117.356 + 122.454 = $481.6 Mil.
Gross Profit was 39.055 + 33.058 + 28.914 + 29.61 = $130.6 Mil.
Total Current Assets was $378.4 Mil.
Total Assets was $535.1 Mil.
Property, Plant and Equipment(Net PPE) was $127.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $137.7 Mil.
Selling, General, & Admin. Expense(SGA) was $380.0 Mil.
Total Current Liabilities was $158.4 Mil.
Long-Term Debt & Capital Lease Obligation was $1,459.9 Mil.
Net Income was -942.107 + -206.511 + -192.183 + -99.817 = $-1,440.6 Mil.
Non Operating Income was -838.684 + -55.951 + -38.973 + 43.235 = $-890.4 Mil.
Cash Flow from Operations was -66.895 + -54.905 + -34.398 + -82.027 = $-238.2 Mil.
Total Receivables was $89.1 Mil.
Revenue was 133.536 + 136.622 + 123.691 + 126.121 = $520.0 Mil.
Gross Profit was 16.58 + 26.282 + 26.575 + 30.015 = $99.5 Mil.
Total Current Assets was $729.7 Mil.
Total Assets was $2,026.3 Mil.
Property, Plant and Equipment(Net PPE) was $223.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $128.4 Mil.
Selling, General, & Admin. Expense(SGA) was $431.9 Mil.
Total Current Liabilities was $113.3 Mil.
Long-Term Debt & Capital Lease Obligation was $1,732.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(82.507 / 481.583) / (89.13 / 519.97)
=0.171325 / 0.171414
=0.9995

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(99.452 / 519.97) / (130.637 / 481.583)
=0.191265 / 0.271266
=0.7051

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (378.399 + 127.085) / 535.115) / (1 - (729.676 + 223.849) / 2026.255)
=0.055373 / 0.529415
=0.1046

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=481.583 / 519.97
=0.9262

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(128.35 / (128.35 + 223.849)) / (137.748 / (137.748 + 127.085))
=0.364425 / 0.520132
=0.7006

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(379.955 / 481.583) / (431.942 / 519.97)
=0.788971 / 0.830706
=0.9498

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1459.874 + 158.419) / 535.115) / ((1732.22 + 113.321) / 2026.255)
=3.024197 / 0.910814
=3.3203

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1440.618 - -890.373 - -238.225) / 535.115
=-0.58309

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Invitae has a M-score of -6.58 suggests that the company is unlikely to be a manipulator.


Invitae Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Invitae's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301

Invitae (Invitae) Headlines